MARC D KOZIN
CIK 1241647 · last filed 2026-06-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$9.14M
Companies
9
Total Filings
86
Lifetime Open-Market Net
-$753.0K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UFPT | Director | 28,112 | $325.00 | $9.14M | -$1.12M | 34 | 2026-06-08 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 3 | 2025-04-21 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | $71.0K | 6 | 2021-12-29 |
| Isleworth Healthcare Acquisition Corp. (ISLEW) Delisted | Director | 0 | $0.00 | $0 | $0 | 1 | 2021-09-10 |
| ENDOCYTE INC (ECYT) Delisted | Director | 0 | — | — | $0 | 7 | 2018-12-21 |
| Tempest Therapeutics, Inc. (MLND) Delisted | Director | 516 | $15.90 | $8.2K | $0 | 1 | 2018-12-11 |
| Tempest Therapeutics, Inc. (OVAS) Delisted | Director | 6,910 | — | — | $189.9K | 23 | 2018-10-02 |
| Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Director | 180 | — | — | $51.2K | 5 | 2018-07-26 |
| DYAX CORP (DYAX) Delisted | Director | 0 | — | — | $56.6K | 6 | 2016-01-22 |
Recent Filings · Page 7 of 9
86 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-07-01 | Salarius Pharmaceuticals, Inc. (FLKS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-12 | UFPT | Grant (A) | +876 | $0 | EDGAR |
| 2015-06-08 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-05-18 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | +2,250 | $0 | EDGAR |
| 2015-05-14 | DYAX CORP (DYAX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-04-09 | Tempest Therapeutics, Inc. (OVAS) Delisted | Buy (P) | +3,000 | $85.3K | EDGAR |
| 2015-04-02 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | +278 | $9.7K | EDGAR |
| 2014-03-06 | Tempest Therapeutics, Inc. (OVAS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-21 | ENDOCYTE INC (ECYT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-14 | UFPT | Grant (A) | +524 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.